In contrast to conventional antiepileptic drugs that typically target single ion channels 65, drugs that target the WDR5-H3K4me3 axis may concurrently mitigate the dysregulation of multiple epilepsy-associated genes, thereby offering a novel therapeutic strategy to overcome the limitations of single-target approaches. Here, WDR5 is linked to epilepsy.